We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros and CHDI Establish Discovery Services Collaboration to Address Huntington’s Disease
Product News

Proteros and CHDI Establish Discovery Services Collaboration to Address Huntington’s Disease

Proteros and CHDI Establish Discovery Services Collaboration to Address Huntington’s Disease
Product News

Proteros and CHDI Establish Discovery Services Collaboration to Address Huntington’s Disease


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Proteros and CHDI Establish Discovery Services Collaboration to Address Huntington’s Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros Biostructures GmbH has announced that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI.

Proteros will apply its integrated discovery platform including proprietary X-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington’s disease (HD).

Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “CHDI has been at the forefront of using a best-in-class network to assist in developing therapies for HD. We welcome the opportunity for Proteros to contribute to this effort.”

Advertisement